US10413523B2 – September 17, 2019 – Enkephalin-influencing composition and method

Please complete the required fields.




Inventors :

Kevin Meehan

Owner :

BIOADATP, LLP, WYOMING

Application Number :

US15814957

Document Number :

US10413523B2

Priority Date :

November 16, 2017

Filing Date :

November 16, 2017

Date of Grant/ Publication :

September 17, 2019

Class :

A61K31 / 352; A61K31 / 198; A61K31 / 197; A61K31 / 675

Abstract

A composition which includes Phenylalanine, Serine, Glutamine and GABA (?-aminobutyric acid). The composition contains the essential amino acids Phenylalanine; Glutamine; the non-essential amino acid Serine; and GABA (?-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin. The composition may further comprise tetrahydrocannabinol (THC).

Claim(s)

1. A pharmaceutical composition for treating pain in a mammal, the pharmaceutical composition comprising: therapeutically effective amounts of: phenylalanine, serine, glutamine, and ?-aminobutyric acid (GABA); in an ingestible delivery form selected from one of a capsule, a tablet, a powder, and a solution in a solvent medium; wherein the composition increases enkephalin activity within the mammal, increases permeability of a blood brain barrier within the mammal, decreases neuronal excitability within the mammal, and increases ?- and ?-opioid receptor activity within the mammal; the proportion by weight of phenylalanine is at least about 50%; the proportion by weight of serine is at least about 1%; the proportion by weight of glutamine is at least about 5%; and the proportion by weight of ?-aminobutyric acid is at least about 35%.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login